Stocks Rebound Widely July 22 As US Presidential Election Evolves – $ADT $INDP $LTRN $MAT $MODD $NFLX $NVDA $TSLA Rise!

By John F. Heerdink, Jr.

The stock market rebounded strongly on July 22, 2024, with the S&P 500 gaining over 1% and the tech-heavy Nasdaq Composite rising approximately 1.6%. This rally was led by mega-cap tech stocks and semiconductor shares, with Nvidia surging more than 4.5% as stories surrounding its development of China centric chips emerged and Tesla climbing over 5% as it is due to report its quarterly results this week. The information technology and communication services sectors were the top performers, while the energy sector declined due to falling oil prices off 3.50% over the last 5-days at $79.95/bbl. Market participants also digested the news of President Biden’s exit from the 2024 presidential race and his endorsement of Vice President Kamala Harris, which had a muted impact on equity and bond markets.

Looking ahead, investors are bracing for a busy week of earnings reports from major companies like Alphabet and Tesla, as well as key economic data releases including second-quarter GDP and the Federal Reserve’s preferred inflation metric.

Market Performance

– Dow Jones Industrial Average: 40,415.44 (+.32%).

– S&P 500: 5,564.41 (+1.08%).

– Nasdaq Composite: 18,007.57 (+1.58%).

– The small caps on the Russell 2000 closed at 2,220.65 (+1.66%). The Russell 2000 had shown impressive gains earlier in the month, up 6.7% in July compared to a modest 0.8% increase for the S&P 500, driven by softer inflation data and speculation about potential changes in the political landscape.

– The iShares Micro-Cap ETF closed at $126.23,+2.14%.

Magnificent Seven

The market leading mega cap Magnificent Seven closed as follows: Alphabet (GOOG) closed at $183.35, +2.21%, Apple (AAPL) closing at $223.96, -.16%, Meta Platforms (META) closing at $487.40, +2.23%, Microsoft (MSFT) closing at $442.94, +1.33%, NVIDIA (NVDA) closing at $123.54, +4.76%, & Tesla’s (TSLA) closed at $251.51, 5.15%. Cathie Wood’s ARK Innovation ETF (ARKK) closed at $47.66, +2.21%.

Notable Stock Movements

Netflix (NFLX) closed at $647.50, +2.24% today after last weeks quarterly results where the streaming behemoth has added a whopping 8.05 million new customers in the second quarter.

Mattell (MAT) closed at $18.68 up +15.10% as rumors that L Catterton is seeking to acquire them surfaced.

Bank Earnings Overview

The second quarter of 2024 saw major U.S. banks reporting their financial results, with several institutions showing improved performance. Bank of America released its Q2 2024 earnings on July 16, demonstrating the ongoing strength of the banking sector.[1] Zions Bancorporation reported net earnings of $1.28 per diluted common share for Q2 2024, an increase from $1.11 in the same quarter of 2023, reflecting improvements in net interest margin, expense management, and credit quality.[2] Cadence Bank also announced positive results, with adjusted net income from continuing operations available to common shareholders of $127.9 million, or $0.69 per diluted common share, representing an 11.3% increase from the previous quarter.[4] These reports suggest a generally robust performance in the banking sector, with institutions benefiting from factors such as improved net interest margins, effective cost management, and stable credit quality.

VP Watchlist Updates

Eupraxia Pharmaceuticals (EPRX, $2.51, -5.99% and is up 9.18% in the aftermarket at $2.74) is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.

Note that Eupraxia recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE trial for treating EoE. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs.

On June 5, Eupraxia announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology (“EULAR”) European Congress of Rheumatology 2024 (the “Meeting”). The EULAR Meeting is being held in Vienna, Austria from June 12-15, 2024.

On May 23, Eupraxia announced that regulators in Australia and Canada have cleared the Company’s request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”). For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com.

Shares of Lantern (LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug program, closed at $4.62, +4.76%.

On July 10, Lantern announced a significant advancement towards the development of a diagnostic for its drug candidate LP-184. The diagnostic is currently based on qRT-PCR (quantitative real-time polymerase chain reaction) technology and is focused on quantifying the amount of PTGR1 RNA in patient tumor samples to assess the potential for sensitivity to Lantern’s drug candidate LP-184. The company plans to further develop and validate the assay for its use as a potential tool for patient selection in later stage clinical trials across a broad range of solid tumors that have shown sensitivity to LP-184. Panna Sharma, CEO of Lantern Pharma stated, “This milestone represents a significant leap forward in our precision oncology approach and in ensuring that we enrich our future LP-184 clinical trials with the patients we believe will be most likely to benefit. By working to develop a companion diagnostic for LP-184, we’re not just advancing a drug candidate; we’re paving the way for more personalized and effective cancer treatments for patients that have the highest likelihood of benefitting from the therapy. The planned use of biomarkers like PTGR1 in our clinical trials exemplifies our commitment to data-driven, patient-centric drug development.”

Panna Sharma, CEO of Lantern, was interviewed recently on the ‘Today In Nashville’, a program hosted by Carole Sullivan and associated with Nashville’s WSMV 4, an NBC affiliate. Watch it here to learn more.

On June 12, Lantern announced that the Japan Patent Office (JPO) has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284 ((+)N-hydroxy-N-(methylacylfulvene)urea). The Certificate of Patent entitled “Illudin Analogs, Uses Thereof, and Methods for Synthesizing the Same” covers molecule LP-284, including claims covering the new molecular entity. A Certificate of Patent is issued after JPO examinations have confirmed the merits of a patent request. Lantern values the broad protection this latest patent provides. Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.

Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $2.18, +2.35% and is up +6.88% at $2.33 in the aftermarket. Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.

On June 4, Indaptus announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company’s lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024. Dr. Waltzman will present preliminary results from the Company’s ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.

On June 3, Indaptus announced updated data from its ongoing Phase 1 clinical trial of Decoy20 in patients with solid tumors. The data were featured in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago, Illinois.

Shares of ADT Inc. (ADT), a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada, closed at $7.90, +2.33% after establishing a new 52-wk high of $7.92 during intraday trading today. On June 17, ADT announced the appointment of Dan Houston and Danielle Tiedt to the Company’s Board of Directors as additional independent directors. In conjunction with their appointments, Houston and Tiedt will both join the Board’s Nominating and Corporate Governance Committee, while Houston will also join the Board’s Compensation Committee. Houston is chairman, president and chief executive officer of Principal Financial Group, a global financial services company with $709 billion of assets under management. He joined Principal in 1984 and has served as chief executive officer since 2015. Houston serves on several boards of non-profit organizations, including the American Council of Life Insurers, Iowa State University Business School Dean’s Advisory Council and Partnership for a Healthier America. As chief marketing officer for Google’s YouTube, Tiedt oversees global marketing strategy, product marketing and brand vision. During her tenure, YouTube has grown to a $40 billion business operating in 76 countries. Prior to joining Google in 2012, Tiedt held various leadership roles in technology product management and marketing at Microsoft. She serves on the board of the 4-H Foundation, America’s largest youth development organization.

Modular Medical, Inc. (NASDAQ: MODD, $1.52, +1.33% and is up 1.97% at $1.55 in the aftermarket), is a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

On July 15, Modular Medical announced a proof-of-concept study with Gubra A/S (“Gubra”) in a high-fat, diet-induced obese (“DIO”) mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. “A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks,” commented Jeb Besser, Chief Executive Officer of Modular Medical. “These discontinuations appear to be due to a combination of tolerability, cost, and inconsistent efficacy. We suspect that short-acting peptides may mitigate many of these side effects and dosage swings by better modulating dosage, but these therapies have generally been abandoned as “too difficult to use” because they required multiple doses per day to be effective. We see the potential for such dosing regimes to be greatly simplified and even improved by the use of pump technology to provide both a basal dose and boluses to control hunger. Using Gubra’s gold-standard DIO mouse model, MODD will seek to determine whether an existing FDA approved, short-acting peptide delivered from a pump platform can provide a more personalized and more tolerable solution for patients who found long acting GLP-1 drugs too difficult to tolerate, while delivering comparable glycemic control and weight loss, specifically for people with type 2 diabetes and obesity.” Learn more here.

On June 3, Modular Medical, Inc. announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

Quote of the Day

“The buried talent is the sunken rock on which most lives strike and founder.” – Frederick William Faber

Economic Reports

On Monday, the July NY Fed Empire State Manufacturing report came in lower than expected at -6.6.

On Tuesday, the June Retail Sales 0.0% & June Retail Sales sans-auto .4%, June Import Prices .0%, June Import Prices sans-oil .2%, June Export Prices -.5%, June Export Prices san-agriculture -.6%, May Business Inventories .5%, the July NAHB Housing Market Index came in lower at 42.

On Wednesday, The Weekly MBA Mortgage Applications Index report logged in higher at 3.9%, the June Housing Starts report confirmed a higher than expected 1.353M, the June Building Permits report logged in with a higher than expected 1.446M, the June Industrial Production report came in higher than expect at .6%, & the June Capacity Utilization report came slightly higher than expected at 78.8%.

On Thursday, the Weekly Initial Claims report came in higher than expected at 243k and the Weekly Continuing Claims report clocked in higher at 1.867M and the market saw further softening. The July Philadelphia Fed Index came in higher at 13.9 & the June Leading Indicators report came in at -.2%.